• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC TO-I/A filed

    2/19/21 5:13:05 PM ET
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PDLI alert in real time by email
    SC TO-I/A 1 a20210219todoc.htm SC TO-I/A Document


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE TO
    (Amendment No. 1)
    (Final Amendment)

    Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1)
    of the Securities Exchange Act of 1934

    PDL BIOPHARMA, INC.
    (Name of Subject Company (issuer))

    PDL BIOPHARMA, INC.
    (Name of Filing Persons (issuer))

    2.75% Convertible Senior Notes due 2021
    (Title of Class of Securities)

    69329Y AG9
    (CUSIP Number of Class of Securities)

    Christopher L. Stone
    Vice President, General Counsel and Secretary
    59 Damonte Ranch Parkway, Suite B-375
    Reno, Nevada, 89521
    (775) 832-8500

    (Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)

    with copies to:

    Karen E. Bertero
    James J. Moloney
    Gibson, Dunn & Crutcher LLP
    333 South Grand Ave.
    Los Angeles, CA 90071
    Telephone: (213) 229-7000



    CALCULATION OF FILING FEE

    Transaction valuation*Amount of filing fee**
    $407,351.25$44.44

    *    Estimated solely for purposes of calculating the filing fee. The repurchase price of the 2.75% Convertible Senior Notes due 2021 (the “Notes”), as described herein, is calculated as the sum of (a) $405,000.00, representing 100% of the principal amount of the Notes outstanding as of January 14, 2021, plus (b) $2,351.25, representing accrued but unpaid interest on the Notes up to, but excluding, February 17, 2021.

    **    The amount of the filing fee, calculated in accordance with Rule 0-11(b) and Rule 1-11(d) of the Securities Exchange Act of 1934, as amended and Fee Rate Advisory #1 for Fiscal Year 2021 equals $109.10 per $1,000,000 of the aggregate value of the transaction.

    ☒    Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    Amount Previously Paid: $44.44
    Filing Party: PDL BioPharma, Inc.
    Form or Registration No.: Schedule TO-I
    Date Filed: January 15, 2021

    ☐    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

    ☐    third-party tender offer subject to Rule 14d-1.
    ☒    issuer tender offer subject to Rule 13e-4.
    ☐    going-private transaction subject to Rule 13e-3.
    ☐    amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s)
    relied upon:

    ☐    Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
    ☐    Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)




    INTRODUCTORY STATEMENT

    This Amendment No. 1 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO originally filed with the Securities and Exchange Commission (the “SEC”) on January 15, 2021 (the “Schedule TO”), and relates to the right of each holder of the Notes (each, a “Holder”), at the Holder’s option, to require the Company to repurchase for cash such Holder’s Notes, or any portion of the principal amount thereof that is equal to $1,000 or an integral multiple of $1,000, on February 17, 2021 (the “Fundamental Change Repurchase Date”), at a price equal to 100% of the principal amount, plus accrued and unpaid interest thereon, if any, up to, but excluding, the Fundamental Change Repurchase Date, pursuant to the terms and conditions of the Fundamental Change Repurchase Right Notice, Notice of Right to Convert and Offer to Repurchase, dated January 15, 2021 (the “Notice”), the Indenture and the Notes.

    This Amendment is intended to satisfy the disclosure requirements of Rule 13e-4(c)(2) under the Securities Exchange Act of 1934, as amended. The Schedule TO, and all the information set forth in the Notice, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below. Every Item in the Schedule TO is automatically updated, to the extent such Item incorporates by reference any section of the Notice that is amended and supplemented therein. All capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Notice.

    Items 1 through 9 and Item 11.

    This Amendment No. 1 amends and supplements Item 4 of this Schedule TO as follows:

    “The Fundamental Change Repurchase Right expired at 5:00 p.m. Eastern Time on February 16, 2021. $142,000 in Notes were validly surrendered for purchase, and not validly withdrawn, pursuant to the Notice. The Company has received conversion notices with respect to $50,000 in Notes.”








    EXHIBIT INDEX

    Exhibit No.Description
    (a)(1)
    Fundamental Change Repurchase Right Notice, Notice of Right to Convert and Offer to Repurchase, dated January 15, 2021, to Holders of 2.75% Convertible Senior Notes due 2021 (incorporated by reference the Schedule TO filed by PDL BioPharma, Inc. with the Securities and Exchange Commission on January 15, 2021) **
    (b)None
    (c)None
    (d)(1)
    Indenture, dated November 22, 2016, by and between PDL BioPharma, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed November 28, 2016) **
    (d)(2)
    First Supplemental Indenture, dated November 22, 2016, by and between PDL BioPharma, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed November 28, 2016) **
    (d)(3)
    Form of 2.75% Convertible Senior Notes due 2021 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed November 28, 2016) **
    (g)None
    (h)None

    ** Previously filed



    SIGNATURES

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:
    February 19, 2021

    PDL BIOPHARMA, INC.
    By:/s/ Dominique Monnet
    Name:Dominique Monnet
    Title:President and Chief Executive Officer


    Get the next $PDLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDLI
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors

      SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive

      12/11/20 8:00:00 AM ET
      $XOMA
      $PDLI
      $ALPN
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PDLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/12/21 3:20:51 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/11/21 4:22:46 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PDLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: L.P. Capital Point Silver bought $383,475 worth of Common Stock (187,061 units at $2.05)

      4 - PDL BIOPHARMA, INC. (0000882104) (Issuer)

      2/3/21 5:57:54 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PDLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PDLI
    SEC Filings

    See more
    • SEC Form SC TO-I/A filed

      SC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)

      2/19/21 5:13:05 PM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:29 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed

      EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)

      2/4/21 12:15:31 AM ET
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care